Product liability government policy

The third policy, the Vaccine Injury Compensation Fund, introduced a government-run, no-fault product liability system that reduced the mean and variance of product liability costs associated with four childhood vaccines polio, diphtheria-tetanus, measles-mumps-rubella, and pertussis. 

To what extent has government intervened in recent years to alter product liability rules or to affect the outcomes of liability claims This section reviews recent policy initiatives of potential relevance to pharmaceutical liability,... 

Review of the effect of external factors on costs and returns on pharmaceutical R D, including new drug regulation, tax policy, product liability law, direct R D subsidies by the National Institutes of Health (NIH) and other government research bodies, and reimbursement policies (both private and public) for prescription drugs. 

These requirements involve government and trade requirements — issues that have increasing importance in global supply chains. Topics include taxes and tariffs, standards for customer protection, efforts to combat terrorism, environmental regulation, social policy, religious customs, and liability law. In some industries, changes here are the single most important determinant of future success. An important consideration can also be RETURN-related issues in areas where the company sells, makes, or sources materials for its products. 

---